Latest Us Growth News

Vitrafy Life Sciences has secured A$30 million through an institutional placement to ramp up manufacturing of its Guardion cryopreservation devices and expand US sales operations, with an additional A$2 million sought via a shareholder plan.

EBR Systems has kicked off a fully underwritten 1-for-2 entitlement offer priced at $0.38 per CDI, aiming to raise $85.6 million to accelerate commercialisation and manufacturing of its wireless cardiac pacing technology.

QuickFee Limited has reported a robust 77% increase in Australian originations for Q4 FY26 to-date, driven by strong Fee Funding and Disbursement Funding growth. The company boosted its Australian credit facility by A$15 million, signalling confidence in its low-risk lending model, while US operations focus on reseller channel expansion amid a product embedding delay.

Syrah Resources has settled an alleged default under its offtake deal with Tesla for natural graphite anode material, with Tesla withdrawing termination threats but retaining rights pending final product qualification.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.

PainChek has secured A$5.5 million via convertible notes to accelerate its US sales expansion and strengthen working capital amid key commercial milestones.

Zip Co’s April update highlights robust US and ANZ market expansion, with total transaction volume surging and credit losses forecast below 1.75%. The company reconfirms FY26 guidance, underpinned by AI-driven underwriting and new subscription offerings.

Helix Resources pushes back against Canex Metals' challenge to its Gold Basin joint venture, affirming compliance with agreements and regulatory standards despite ongoing takeover tensions.

Ava Risk Group posted a $6.1 million Q3 sales intake and secured a $7 million strategic investment to fuel US expansion, while geopolitical tensions delay some Middle East orders.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

ImpediMed reported a $3.5 million revenue in Q3 FY26, with reimbursement coverage in the US reaching 94.3%, supporting growth in heart health and weight management markets. New CEO Erik Anderson aims to accelerate commercial momentum and drive cash flow break-even.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.